The collaboration is focused on developing five new types of advanced microbial-resistant plastics
Impact BioMedical initiates bioplastics research collaboration with one of world’s largest plastic manufacturers. (Credit: kropekk_pl from Pixabay.)
Document Security Systems (DSS), a company operating businesses focusing on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets, announced its wholly owned subsidiary Impact BioMedical, through its subsidiary Impact BioLife Science (Impact BioLife), initiated a bioplastics research collaboration with one of the world’s largest plastic manufacturers. The collaboration is focused on developing five new types of advanced microbial-resistant plastics.
The bioplastics research collaboration builds upon existing research of Daryl Thompson, founder of advance research company, GRDG Sciences (GRDG), and Impact BioLife’s Director of Scientific Initiatives. Notably, Thompson has been twice nominated for the Nobel Prize for his work in cutting-edge organic and carbohydrate chemistry.
“We are developing antimicrobial plastics for consumer products that control the spread of active pathogens such as SARS-CoV-2, Influenza, E. coli, Staph, and Rhinovirus,” stated Thompson. “We are researching and exploiting key strategies found in the biological realm that can create plastics that are highly beneficial. Under this collaboration, we are specifically looking at solutions for common products such as cups, plates, utensils, plastic bags, and even counter tops, which together represent a significant and timely market opportunity. We are targeting to complete our research and testing phase early in the fourth quarter, setting the stage to quickly move into negotiations for global licensing and royalty agreements.”
GRDG is a specialized research team that focuses on developing solutions for biodefense under the guidelines of the Project BioShield Act, Event 201, and Potomac Institute for Policy Studies.
GRDG performs rapid analysis and research by using advanced algorithms and the most complete databases in the world. The team operates in a lean and efficient manner and when necessary utilizes the top contract research organizations to deliver solid results that are robust and accurate.
GRDG’s Chief Scientific Advisor Dr. Roscoe M. Moore, Jr., the former United States Assistant Surgeon General and former Epidemic Intelligence Service Officer at Centers for Disease Control and Prevention or CDC commented, “Research to date affirms our belief that our bioplastics technology can be a major game changer for a wide variety of consumer products and even beyond.”
“Consumers have a newly heightened awareness of the importance of microbial-resistant products and surfaces, and the patented bioplastics we are developing could provide an extremely effective solution to meet this growing unmet need,” commented Jason Grady, Chief Operating Officer of DSS.
Source: Company Press Release